NCT03784079 - A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

February 6, 2020

Study Completion Date

February 6, 2020

Conditions

HIV Infections

Interventions

DRUG

GSK3640254

GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.

DRUG

Placebo matching GSK3640254 Mesylate salt

Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water

Trial Locations (23)

2113

GSK Investigational Site, Johannesburg

4001

GSK Investigational Site, Durban

9301

GSK Investigational Site, Bloemfontein

13003

GSK Investigational Site, Marseille

20127

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

28006

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

32803

GSK Investigational Site, Orlando

41013

GSK Investigational Site, Seville

59208

GSK Investigational Site, Tourcoing

60590

GSK Investigational Site, Frankfurt am Main

75018

GSK Investigational Site, Paris

81675

GSK Investigational Site, Munich

93301

GSK Investigational Site, Bakersfield

00149

GSK Investigational Site, Rome

03010

GSK Investigational Site, Alicante

08916

GSK Investigational Site, Badalona

08025

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona